Gene therapy market products are expected to boost the growth of the global Gene Therapy market at a CAGR of 19.04% during the forecast period 2024 to 2032

Market Research Future (MRFR) has published a cooked research report on the “Global Gene Therapy Market” that contains the information from 2019 to 2032. The Gene Therapy market is estimated to register a CAGR of 19.04% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the Global Gene Therapy Market— Bristol-Myers Squibb Company (US), Lonza (Switzerland), UniQure N.V. (Netherlands), Bluebird Bio, Inc. (US), Orchard Therapeutics Plc (UK), GenSight Biologics (France), Novartis AG (Switzerland), Amgen Inc. (US), Sarepta Therapeutics Inc. (US), and Spark Therapeutics, Inc. (US).

Gene Therapy Market Latest Highlights

The global Gene Therapy market is expected to register a CAGR of 19.04% during the forecast period and is estimated to reach USD 29.36 billion by 2032.

The growing incidences and prevalence of cancer and rare disorders, increasing approval for gene therapy products, and favorable government support for gene therapy are fueling the growth of the gene therapy market. Additionally, the clinical trial failures associated with gene therapy and the challenges associated with gene therapy delivery are a restraining factor for the market. However, the growing investment in the field of gene therapy and ongoing clinical trials associated with gene therapy will provide growth opportunities for the market in the future.

Segment Analysis

The global gene therapy market has been segmented based on Vector Type, Gene Type, Application, and Delivery Mode.

On the basis of the vector type, the market is segmented into viral vector and non-viral vector. The viral vectors segment held the majority share in the market in 2023. Viral vectors are more dominant than non-viral vectors in gene therapy due to their superior efficiency in delivering genetic material into target cells. Viral vectors, such as adenoviral, adeno-associated viral (AAV), and lentiviral vectors, have evolved to effectively penetrate cell membranes and integrate or express their genetic payloads within cells. This high efficiency and capacity for gene delivery make them the preferred choice for many therapeutic applications.

On the basis of the gene type, the market is segmented into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors and others. The antigen segment held the largest market share in 2023 and is the fastest-growing segment during the forecast period. Increasing prevalence of cancer and infectious diseases is fueling demand for targeted and effective treatment options. Antigen-based gene therapies offer promising solutions for these challenging conditions by targeting disease-specific antigens and shift towards personalized medicine, which aims to tailor treatments to individual patient profiles, is driving interest in antigen-based therapies.

On the basis of application, the market is segmented into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious diseases, and others. The others segment held the largest market share in 2023, and oncological disorders segment is the fastest-growing segment during the forecast period i.e., 2024-2032. Gene therapy offers a novel approach to address unmet medical needs by targeting the genetic and molecular mechanisms driving cancer. Moreover, innovations in gene editing technologies, such as CRISPR-Cas9, TALENs, and base editors, enable precise modifications to cancer-related genes.

On the basis of the delivery method, the market is segmented into in vivo gene therapy and ex vivo gene therapy. The in vivo gene therapy segment held the largest market share in 2023 and is the fastest-growing segment during the forecast period i.e., 2024-2032. Increased awareness of the potential benefits of in vivo gene therapy drives demand for novel treatments and diverse range of indications, including oncology, neurology, cardiology, and rare genetic disorders. The broadening scope of target indications drives market growth and opens new business opportunities.

Access full report @ https://www.marketresearchfuture.com/reports/gene-therapy-market-8399

Regional Analysis

The global Gene Therapy market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Gene Therapy market comprises of Germany, France, the UK, Italy, Spain, and the Rest of Europe. The Gene Therapy market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Gene Therapy market comprises of Middle East, Africa, and Latin America.

North America Gene Therapy market is experiencing significant growth, driven by factors such as rise in the prevalence of chronic disease, availably of reimbursements for the gene therapy and rise in healthcare expenditure and research development activities for gene therapy drugs across the region.  In recent years, there has been a significant increase in the number of drugs in development for gene therapy, which has driven the growth of the gene therapy market. The pipeline of gene therapy drugs includes a wide range of treatments for various genetic and acquired diseases, such as rare genetic disorders, cancer, and autoimmune diseases. The potential of these drugs to provide targeted and personalized treatments for patients with complex medical conditions has generated significant interest from biopharmaceutical companies, investors, and healthcare providers. The competitive landscape features established players who have adopted strategies such as acquisition, agreement, strategic alliance, collaboration, clinical trial, expansion, joint venture, new product development, and product approval to expand their product portfolio.

Europe Gene Therapy market is witnessing notable growth, fueled by various factors. Strong infrastructure with renowned universities, research institutions and biotechnology hubs, and skilled workforce comprising scientists, clinicians, and industry professionals. The ongoing research and technological advancements in genomics and molecular biology are accelerating the development of innovative gene therapies. Improved understanding of gene functions and disease mechanisms leads to more targeted and effective treatments. Increasing investments, by both public and private sectors, are transforming the market, providing significant funding, which supports clinical trials and the commercialization of gene therapies.

The Asia Pacific Gene Therapy market is experiencing substantial growth, propelled by a confluence of factors that underscore the increasing demand for Gene Therapy in the region. The APAC region has a high incidence of genetic and rare diseases, including inherited conditions like thalassemia and various cancers. This creates a strong demand for innovative treatments such as gene therapy. Additionally, Increased investments in healthcare infrastructure and biotechnology in countries like China, India, and Japan are supporting the development and adoption of advanced therapies, including gene therapy. Several APAC countries are implementing policies to promote biotech innovation and gene therapy research. Governments are offering grants, subsidies, and incentives to support clinical trials and commercialization of gene therapies.  

Moreover, the Rest of the World is segmented into the Middle East & Africa, and South America. The Gene Therapy market in the Middle East and Africa is experiencing growth driven by several key factors. Rising disposable income and improved healthcare infrastructure across the region are driving demand for gene therapy. The growing R&D capabilities and the establishment of biotech hubs in countries like the UAE and Saudi Arabia are accelerating the development of gene therapies. Rising awareness and advocacy for rare diseases are creating a demand for new treatment options, including gene therapies.

Key Findings of the Study

• 
  

  The global Gene Therapy market is expected to reach USD 29.36 billion by 2032, at a CAGR of 19.04% during the forecast period.

  
  


• 
  

  The Asia-Pacific region accounted for the fastest-growing global market.

  
  


• 
  

  Based on application, the antigen segment was attributed to holding the largest market in 2023.

  
  


• 
  

  Novartis AG (Switzerland), Spark Therapeutics, Inc. (US), Bristol-Myers Squibb Company (US), Amgen, Inc. (US), and Bluebird Bio, Inc. (US) are the key market players.